-1.82%
-9.40%
-10.00%
-25.41%
-3.91%
-42.18%
-71.96%
AI Spotlight on ACIU
Company Description
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding.Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.The company is developing Crenezumab, a humanized, conformation-specific monoclonal antibody, which is in Phase II clinical prevention trial for the treatment of Alzheimer's disease (AD).
It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase II clinical study for AD, as well as completed Phase Ib clinical study for Down syndrome; ACI-35, an anti-Tau vaccine candidate that has completed Phase Ib clinical study; and Tau- positron emission tomography (PET) imaging tracer, which is in Phase II clinical study.In addition, the company is researching and developing small molecule Tau aggregation inhibitors for AD and NeuroOrphan indications.Further, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3.
AC Immune SA has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; Eli Lilly and Company; and WuXi Biologics.The company was incorporated in 2003 and is headquartered in Lausanne, Switzerland.
Market Data
| Last Price | 2.7 |
| Change Percentage | -1.82% |
| Open | 2.72 |
| Previous Close | 2.75 |
| Market Cap ( Millions) | 269 |
| Volume | 147515 |
| Year High | 4.98 |
| Year Low | 2.25 |
| M A 50 | 2.92 |
| M A 200 | 3.28 |
Financial Ratios
| FCF Yield | 17.51% |
| Dividend Yield | 0.00% |
| ROE | -28.53% |
| Debt / Equity | 2.37% |
| Net Debt / EBIDTA | 74.91% |
| Price To Book | 2.09 |
| Price Earnings Ratio | -6.81 |
| Price To FCF | 5.71 |
| Price To sales | 6.0 |
| EV / EBITDA | -5.53 |
News
- Jan -31 - New Strong Buy Stocks for January 31st
- Nov -14 - AC Immune's Active Immunotherapy Shows Antibody Responses In Early Parkinson's Patients
- Aug -06 - AC Immune (ACIU) Reports Q2 Loss, Lags Revenue Estimates
- Jul -31 - AC Immune Unveils Novel Therapeutic Antibody Drug Conjugate (ADC) Technology for Improved Efficacy in Neurodegenerative Diseases at AAIC 2024
- Jul -26 - AC Immune: Takeda Partnership Brings Funds To Drive Pipeline Forward
- Jul -25 - AC Immune's ACI-35.030 (now “JNJ-2056”) Granted FDA Fast Track Designation for Alzheimer's Disease
- May -28 - AC Immune to Present at the Jefferies Global Healthcare Conference in June 2024
- May -13 - Alzheimer's vaccine licensing deal boosts AC Immune
- May -13 - Why Is AC Immune (ACIU) Stock Up 45% Today?
- May -13 - AC Immune Reports First Quarter 2024 Financial Results and Provides a Corporate Update
- May -13 - AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer's Disease
- May -13 - AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer's Disease
- Mar -14 - AC Immune Reports Full Year 2023 Financial Results and Provides a Corporate Update
- Feb -22 - AC Immune Announces Upcoming Presentations at AD/PD™ 2024
- Jan -30 - Down -35.7% in 4 Weeks, Here's Why AC Immune (ACIU) Looks Ripe for a Turnaround
- Jan -22 - AC Immune to Regain Global Rights to Crenezumab and Semorinemab
- Jan -18 - AC Immune (ACIU) is a Great Momentum Stock: Should You Buy?
- Jan -08 - 5 Small-Cap Stocks to Play the January Effect
- Jan -03 - AC Immune (ACIU) Upgraded to Buy: Here's Why
- Jan -03 - AC Immune Progress Update on Phase 2 Active Immunotherapy Clinical Pipeline for Alzheimer's and Parkinson diseases
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Therapeutic and Diagnostic Products
Expected Growth : 9.33 %
What the company do ?
AC Immune SA's Therapeutic and Diagnostic Products focus on developing innovative treatments for neurodegenerative diseases, such as Alzheimer's, using SupraAntigen and Antibody technologies.
Why we expect these perspectives ?
AC Immune SA's Therapeutic and Diagnostic Products segment growth of 9.33% is driven by increasing demand for Alzheimer's and Parkinson's disease treatments, advancements in antibody-based therapies, and strategic partnerships with pharmaceutical companies. Additionally, growing investments in research and development, and expansion into new markets contribute to the segment's growth.
Ac Immune Sa Products
| Product Range | What is it ? |
|---|---|
| SupraAntigen-based vaccines | AC Immune's SupraAntigen-based vaccines are designed to stimulate a strong immune response against specific targets, such as beta-amyloid in Alzheimer's disease. |
| Antibody-based therapies | AC Immune's antibody-based therapies are designed to target specific proteins involved in neurodegenerative diseases, such as alpha-synuclein in Parkinson's disease. |
| Small molecule-based therapies | AC Immune's small molecule-based therapies are designed to modulate specific biological pathways involved in neurodegenerative diseases, such as the Tau protein in Alzheimer's disease. |
| Diagnostic biomarkers | AC Immune's diagnostic biomarkers are designed to detect and monitor neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. |
| Tau-targeting therapies | AC Immune's Tau-targeting therapies are designed to prevent the aggregation of Tau protein, a hallmark of Alzheimer's disease. |
| Abeta-targeting therapies | AC Immune's Abeta-targeting therapies are designed to prevent the aggregation of beta-amyloid protein, a hallmark of Alzheimer's disease. |
AC Immune SA's Porter Forces
Threat Of Substitutes
The threat of substitutes for AC Immune SA is moderate, as there are alternative treatments and therapies available for Alzheimer's disease and other neurodegenerative disorders.
Bargaining Power Of Customers
The bargaining power of customers is low, as AC Immune SA is a biotech company that develops novel therapeutic approaches for neurodegenerative diseases, and customers have limited alternatives.
Bargaining Power Of Suppliers
The bargaining power of suppliers is moderate, as AC Immune SA relies on a few key suppliers for raw materials and services, but has some flexibility to negotiate prices and terms.
Threat Of New Entrants
The threat of new entrants is high, as the biotech industry is highly competitive, and new companies are constantly emerging with innovative technologies and approaches.
Intensity Of Rivalry
The intensity of rivalry is high, as AC Immune SA operates in a highly competitive industry with many established players, and must continually innovate and differentiate itself to remain competitive.
Capital Structure
| Value | |
|---|---|
| Debt Weight | 2.13% |
| Debt Cost | 5.03% |
| Equity Weight | 97.87% |
| Equity Cost | 9.90% |
| WACC | 9.79% |
| Leverage | 2.18% |
AC Immune SA : Quality Control
AC Immune SA passed 3 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| BRNS | Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in developing novel T cell immunotherapeutics to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. It is advancing … |
| IDIA.SW | Idorsia Ltd, a biopharmaceutical company, discovers, develops, and commercializes drugs for unmet medical needs in Switzerland. The company has a clinical development pipeline that cover various therapeutic areas, including CNS, … |
| IMTX | Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company … |
| RVU.WA | Ryvu Therapeutics S.A., a clinical stage biopharmaceutical company, engages in developing of novel small molecule therapies for treatment in oncology. Its lead candidate, RVU120, is a CDK8 kinase inhibitor with … |
| GNS.L | Genus plc operates as an animal genetics company in North America, Latin America, the United Kingdom, rest of Europe, the Middle East, Russia, Africa, and Asia. The company operates through … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
Barinthus Bio
A-Score
1-Year Total Return ->
🥈
Idorsia
A-Score
1-Year Total Return ->
🥉
AC Immune
A-Score
1-Year Total Return ->
4
Immatics
A-Score
1-Year Total Return ->
5
Ryvu Therapeutics
A-Score
1-Year Total Return ->
6
